|
Taro Receives Final Approval for Mometasone Furoate Topical Solution USP, 0.1% (Lotion) ANDA; Generic Equivalent to Elocon(R) Lotion |
|
|
|
16 Mar 2006 |
HAWTHORNE, NY, NY, USA | Mar 15, 2006 | Taro Pharmaceutical Industries Ltd. ("Taro," Nasdaq: TARO) reported today that Taro Pharmaceuticals U.S.A., Inc. ("Taro USA"), its U.S. affiliate, has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for Mometasone Furoate Topical Solution USP, 0.1% (Lotion) ("mometasone lotion").
Taro's mometasone lotion is a prescription topical corticosteroid product used primarily for the relief of inflammatory skin conditions. The Taro product is bioequivalent to Schering-Plough's Elocon(R) lotion. According to industry sources, annual U.S. sales of mometasone lotion products are approximately $9.6 million.
Taro had received tentative approval of its ANDA for this product in December 2004. Taro USA also has ANDA approvals for Mometasone Furoate Ointment USP, 0.1% and Mometasone Furoate Cream USP, 0.1%.
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
For further information on Taro Pharmaceutical Industries Ltd., please visit the Company's website at www.taro.com.
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's mometasone furoate products. Although Taro Pharmaceutical Industries Ltd. believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurance that its expectations will be attained. Factors that could cause actual results to differ include industry and market conditions; slower than anticipated penetration of new markets; physician, pharmacist or patient acceptance of Taro's mometasone furoate products; changes in the Company's financial position; regulatory actions; and, other risks detailed from time to time in the Company's SEC reports, including its Annual Reports on Form 20-F. Forward-looking statements speak only as of the date on which they are made. The Company undertakes no obligation to update, change or revise any forward-looking statements, whether as a result of new information, additional or subsequent developments or otherwise.
CONTACT: Taro Pharmaceutical |
